Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a Healthcare company (Biotechnology) with a market capitalization of $97M. The Maz Rating grades it against the other companies in its sector.
Unicycive Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.55, Unicycive Therapeutics, Inc. trades at 1.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -88.8%, return on invested capital of -61.4% and a free cash flow yield of -28.6%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 3.81. Over the past 52 weeks the share price ranged from $3.33 to $8.74, with a beta of 1.86.
Unicycive Therapeutics, Inc. does not currently pay a dividend.
8 Wall Street analyst ratings cover the stock: 8 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.